Alpha-GPC for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Alpha-GPC for Health & Longevity

Created on 07/16/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A highly absorbable choline compound the body uses to make a key brain-signaling chemical for memory and focus. Its best evidence is in older adults with memory loss after stroke or early dementia, showing modest gains; benefits in healthy people are unproven. Generally well tolerated, but a possible stroke-risk question remains unresolved. (Full Review)

Protocol

Cognitive Dose
300–600 mg
Single dose, 30–60 min before demanding mental work; used intermittently
Pre-Exercise Dose
~600 mg
Taken 30–90 min before exercise
Best Time
Morning / early afternoon
Late-evening dosing risks sleep disruption
Time to effect
Cognitive Benefit (Clinical)
Weeks–months
Measured over continued use in clinical populations
Acute Focus & Performance
30–90 min
Acute effects, if present, occur within this window of a dose
Growth Hormone Rise
1–2 hours
Brief transient rise after a ~600 mg dose

Benefits

Contraindications
  • History of stroke or transient ischemic attack
  • Uncontrolled hypertension
  • Significant atrial fibrillation
  • High cerebrovascular risk (e.g., prior stroke within 90 days, poorly controlled blood pressure)
  • Bipolar disorder or active depression
  • Pregnancy or breastfeeding
    •
Key Interactions
  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)
  • Other cholinergic supplements (citicoline/CDP-choline, choline bitartrate, huperzine A, high-dose alpha-lipoic acid)
  • Anticholinergic drugs (scopolamine, atropine, first-generation antihistamines, tricyclic antidepressants, oxybutynin)
  • Anticoagulant/antiplatelet agents (warfarin, aspirin, clopidogrel)
  • OTC anticholinergic antihistamines and sleep aids (diphenhydramine, doxylamine)
    •

Risk & Side Effects

  • High:
  • Medium: Association with increased stroke risk; gastrointestinal distress
    •
  • Low: Headache & dizziness; cholinergic overstimulation
    •
  • Speculative: TMAO-mediated cardiovascular risk; mood destabilization in cholinergic-sensitive individuals
    •

Monitoring

Marker Target Why
Blood pressure <120/80 mmHg Central to the main stroke-risk concern
Fasting homocysteine <7–8 µmol/L Methylation and vascular risk tied to choline metabolism
TMAO As low as feasible (~<6 µmol/L) Reflects the choline→TMAO pathway underlying the vascular concern
ApoB <80 mg/dL (lower if high-risk) Best single marker of atherosclerotic particle burden and stroke risk
Fasting glucose / HbA1c HbA1c <5.4% Vascular risk factor relevant to the stroke concern
Cognitive assessment (MoCA) ≥26 / 30 Tracks the cognitive endpoint the intervention targets

Cadence: Baseline, then ~3 months, then every 6–12 months; more frequent blood-pressure checks in those with cardiovascular risk

Qualitative Assessment

  • Subjective focus, attention, and mental clarity during demanding tasks
  • Working memory and word-finding in daily life
  • Perceived training quality, power, and mind-muscle connection (for ergogenic use)
  • Sleep quality (as a check that dosing timing is not causing disruption)
  • Mood stability, especially in anyone with a history of mood disorders
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.